The standard medical narrative describes type 2 diabetes as a chronic, progressive disease. That description is accurate for most patients under current treatment. It is not accurate as a description of the biology.

Type 2 diabetes is a metabolic disease that responds to metabolic inputs. It develops slowly, over years, through a process that is visible in the blood long before the clinical threshold is crossed. And it can be reversed, not merely managed, when that process is interrupted with sufficient force and sufficient timing.

Remission has now been demonstrated in randomized controlled trials. The biology that explains why it works is well-established. What remains underdiscussed is how long the window is open, what closes it, and what interventions are large enough to matter.

This article covers all three.

The system under stress

The mechanics of insulin signaling are covered in detail in the metabolic health article. The short version: insulin binds to receptors on skeletal muscle, liver, and adipose tissue and triggers the movement of glucose transporter 4, GLUT4, to the cell membrane. GLUT4 is the channel through which glucose enters the cell. Without a complete insulin signal, that channel largely stays closed.

In insulin resistance, the signal stalls. The best-characterized mechanism involves ectopic fat: when adipose tissue saturates and fat begins accumulating in skeletal muscle and liver, it generates diacylglycerol, which activates PKC-theta, which phosphorylates the insulin receptor substrate at a serine residue rather than the tyrosine residue required for normal signaling. GLUT4 does not move. Glucose stays in the bloodstream.

The pancreas responds to elevated blood glucose by releasing more insulin. This additional output partially overcomes the impaired signaling and keeps blood glucose in a range that looks normal on a lab report. The system is compensating. The cost of that compensation is invisible unless you measure it: fasting insulin is elevated, sometimes substantially, years before fasting glucose moves.

The beta cell’s long overtime

The compensation mechanism is more durable than most people realize, and that durability is precisely the problem.

Pancreatic beta cells can sustain hyperinsulinemia, a state of chronically elevated insulin output, for years before glucose regulation visibly breaks down. A prospective study following 6,538 participants in the Whitehall II cohort found that HOMA-IR was elevated more than ten years before type 2 diabetes diagnosis. Fasting glucose did not start rising meaningfully until two to three years before the clinical threshold.^[3] The insulin resistance had been present and measurable for a decade while the glucose test reported nothing of concern.

During that period, beta cells are running at two to five times their normal output. Sustained high-rate secretion generates oxidative stress and endoplasmic reticulum stress. A misfolded protein aggregate called islet amyloid polypeptide, IAPP, accumulates in the islets. Functional beta cell mass declines slowly, and the decline is not linear: there appears to be a threshold below which the remaining cells can no longer sustain compensation, at which point glucose rises and the clinical diagnosis arrives.

That diagnosis marks the end of a long process, not the beginning of a problem.

Where the fat goes

The mechanistic link between excess weight and type 2 diabetes is not obesity per se. It is ectopic fat deposition: fat in places the body is not designed to store it.

Roy Taylor at Newcastle University developed what he calls the twin cycle hypothesis, based on a series of studies using MRI to measure organ-level fat.^[4] The hypothesis holds that type 2 diabetes is driven by two connected cycles: liver fat causes hepatic insulin resistance and drives elevated fasting glucose by impairing insulin’s ability to suppress hepatic glucose production overnight; pancreatic fat accumulates in parallel and impairs first-phase insulin secretion, the rapid burst of insulin that normally occurs within minutes of a meal.

The crucial feature of this model is that both deposits are reversible. They accumulated because of chronic caloric excess, and they can be cleared with sustained caloric deficit. When they clear, hepatic insulin resistance resolves, first-phase insulin secretion recovers, and glucose regulation normalizes. Taylor’s MRI studies in 2011 and 2016 showed that pancreatic fat removal preceded beta cell recovery: the fat leaves first, and the function follows.^[4]

This is not a hypothesis about weight as a proxy. It is a hypothesis about specific fat depots in specific organs, and about what happens when those depots are emptied.

The scale of the problem

537 million adults worldwide had diabetes in 2021, according to the International Diabetes Federation. Approximately 90 percent of those cases are type 2.^[5] An additional 374 million had impaired glucose tolerance, the pre-diabetic state that sits on the same trajectory.

Prevalence has roughly doubled every 20 years in high-income countries, despite awareness campaigns, screening programs, and the wide availability of metformin. The standard clinical response, a combination of metformin, dietary advice, and monitoring, slows progression. It rarely reverses the underlying disease. Most clinical guidelines still describe type 2 diabetes as chronic and progressive, which is an accurate description of its natural history under that standard of care.

What actually works

Caloric restriction and weight loss

The most important trial in this area is DiRECT, published in The Lancet in 2018 by Lean and colleagues.^[1] The trial enrolled 298 participants with type 2 diabetes of less than six years’ duration, randomized them to intensive dietary management or usual care, and used a primary outcome that few trials in this space had used before: remission, defined as HbA1c below 48 mmol/mol without diabetes medication.

The dietary intervention was aggressive: a formula diet of approximately 800 kcal per day for three to five months, followed by structured food reintroduction and long-term support. At one year, 46 percent of the intervention group was in remission. At two years, 36 percent remained in remission. Among those who lost 15 kg or more, the remission rate was 86 percent.

These are not marginal effects. This is the first large randomized trial to demonstrate that type 2 diabetes remission is achievable as a primary outcome through a structured non-surgical intervention. The mechanism is precisely what Taylor’s model predicts: sufficient caloric deficit clears ectopic liver and pancreatic fat, first-phase insulin secretion recovers, and glucose regulation normalizes without medication.

The weight loss threshold matters. Modest weight loss, around 5 percent of body weight, produces modest metabolic improvements. The DiRECT data suggest that clearing enough liver and pancreatic fat to restore beta cell function requires a larger deficit, and that the 15 kg threshold is where the biological change becomes reliable rather than likely.

The DIRECT-Plus trial, led by Iris Shai and colleagues, examined a Mediterranean plus green plant diet and found significant reductions in pancreatic fat measured by MRI, consistent with Taylor’s model and with meaningful metabolic improvement.

Exercise

Exercise acts on glucose disposal through two mechanisms that are independent of each other and partially independent of weight loss.

The first is acute GLUT4 translocation. During exercise, the AMPK pathway activates GLUT4 translocation independently of insulin, the same end result achieved through a different upstream mechanism. A single moderate-intensity exercise session improves insulin sensitivity for 24 to 72 hours. The effect is real and measurable, and it occurs without any change in body weight.

The second is structural: resistance training increases skeletal muscle mass, and skeletal muscle is the largest glucose disposal organ in the body. More muscle means greater capacity to clear glucose from the bloodstream after meals. This is not a small or transient effect. Muscle mass built through progressive resistance training persists and compounds over time.

The strongest long-term evidence on exercise comes from the Da Qing study, now with a 40-year follow-up. Pan and colleagues randomized 577 Chinese adults with impaired glucose tolerance in 1986 into diet only, exercise only, diet plus exercise, or control groups, and followed them for four decades.^[6] The combined diet and exercise group reduced type 2 diabetes incidence by 39 percent and cardiovascular mortality by 33 percent over the full follow-up period. Those numbers represent a population-level effect from a lifestyle intervention, persisting for 40 years.

Both aerobic exercise and resistance training contribute. The evidence consistently shows that combined training is superior to either modality alone. The resistance training article at /en/2026-06-resistance_training covers the structural evidence in detail.

Dietary composition

The role of dietary composition is real but secondary to total caloric balance and resulting weight loss for the purposes of type 2 diabetes reversal. That said, composition matters in ways that affect how practical and sustainable a dietary intervention is.

The Virta Health trial, published by Hallberg and colleagues in Diabetes Therapy in 2018, enrolled 349 patients with type 2 diabetes and randomized them to a continuous remote care intervention featuring a very low-carbohydrate diet or to usual care.^[2] At one year, 60 percent of the intervention group had reduced or eliminated their diabetes medications. 94 percent of those on insulin had reduced or eliminated their insulin dose. HbA1c fell significantly. The mechanism is partly direct: a very low carbohydrate intake reduces postprandial glucose load, lowering the demand on an already-stressed beta cell population and creating a more favorable glycemic environment.

The Mediterranean dietary pattern has the longest observational track record. The PREDIMED trial, with 7,447 participants at high cardiovascular risk, found that Mediterranean diet supplemented with olive oil or nuts reduced the incidence of major cardiovascular events by approximately 30 percent compared with a low-fat control diet.^[8] Rates of type 2 diabetes incidence were also lower in the Mediterranean groups.

The honest synthesis: for someone who already has type 2 diabetes, the dietary intervention needs to be large enough to drive meaningful weight loss, or specifically structured to reduce glucose load enough to give beta cells relief. Low-carbohydrate achieves both. Mediterranean achieves the latter more moderately. The best diet is the one that can be sustained, but the intervention needs to be sufficient to matter.

Sleep

Sleep restriction is a metabolic stressor that does not receive adequate clinical attention.

A landmark study by Spiegel and colleagues published in The Lancet in 1999 showed that restricting healthy young men to six hours of sleep per night for six consecutive days produced measurable impairment in glucose tolerance and insulin secretion, with the degree of impairment comparable to early-stage type 2 diabetes.^[7] The changes resolved with sleep recovery.

Even short-term sleep debt degrades glucose regulation. Chronic sleep restriction adds a continuous metabolic stressor to a system that may already be under stress from insulin resistance. The sleep biomarkers article at /en/2026-06-sleep_biomarkers covers the evidence in detail. For type 2 diabetes management and prevention, sleep duration and quality are not secondary considerations.

Pharmacology: what the drugs actually do

Metformin reduces hepatic glucose output and modestly improves insulin sensitivity. It is cheap, safe, and well-tolerated. The Diabetes Prevention Program, a large RCT published in the New England Journal of Medicine in 2002 by Knowler and colleagues, randomized 3,234 adults with impaired glucose tolerance to metformin, intensive lifestyle intervention, or placebo.^[9] Metformin reduced diabetes incidence by 31 percent compared with placebo. Intensive lifestyle intervention reduced it by 58 percent. Metformin is a useful preventive tool. It is not a reversing agent.

GLP-1 receptor agonists represent a qualitative change in pharmacological capability. Semaglutide and tirzepatide produce substantial weight loss in a meaningful proportion of patients, 10 to 15 percent of body weight on semaglutide, 20 percent or more on tirzepatide in trial conditions. That degree of weight loss can clear sufficient ectopic fat to produce remission through the same pathway as DiRECT. The pharmacology does not change the mechanism. It enables the weight loss that enables the mechanism.

These drugs are not discussed here as substitutes for lifestyle change. They are discussed as tools that can achieve the metabolic threshold that makes reversal possible, particularly for patients for whom diet-driven weight loss of 15 kg has proved impossible to sustain. The biology of remission is the same either way.

The window, and what closes it

The reversibility of type 2 diabetes depends on beta cell function, and beta cell function is not uniformly recoverable.

Taylor’s model specifies that first-phase insulin secretion is recoverable when pancreatic fat is removed, and the DiRECT trial results are consistent with this in patients with diabetes duration under six years. The DiRECT eligibility criterion was not arbitrary. Beta cell exhaustion, the endpoint of years of overwork under conditions of chronic ectopic fat and insulin resistance, produces irreversible functional loss. Cells that have undergone the full amyloid deposition and oxidative stress pathway cannot be restored by weight loss. They are gone.

This creates a time-dependent structure to the opportunity. Early in the course of type 2 diabetes, when beta cell function is impaired but not exhausted, reversal is consistently achievable with sufficient intervention. Later in the course, when beta cell mass has declined substantially, reversal becomes partial at best: some improvement in glucose regulation, but not remission.

The same logic applies to the pre-diabetic period. The 374 million people with impaired glucose tolerance are on the same trajectory as the 537 million with diabetes, but they are earlier in the process. Their beta cells are stressed but not exhausted. Their ectopic fat depots are real but not maximal. The Da Qing 40-year data show that intervention at this stage produces durable, large-magnitude reductions in both diabetes incidence and cardiovascular mortality. Waiting for the diagnosis before intervening forfeits the period when the intervention works most cleanly.

The standard clinical model still treats the pre-diabetic period as a monitoring interval rather than an intervention opportunity. That is a category error about what the biology permits.

What “remission” means and does not mean

Remission is defined as HbA1c below 48 mmol/mol without diabetes medication, sustained for at least three months. It means glucose regulation has normalized. It does not mean the underlying metabolic vulnerability has disappeared.

A person who achieves remission through 15 kg of weight loss and then regains that weight will, in most cases, return to a diabetic or pre-diabetic metabolic state. The DiRECT two-year data are instructive here: participants who maintained their weight loss maintained their remission; those who regained weight did not. Remission is a state that requires continued behavioral conditions to maintain, not a cure that resolves the underlying susceptibility.

This is not a reason to dismiss remission as a goal. A decade in remission, with normal glucose regulation, is a decade without the microvascular complications, the cardiovascular risk amplification, and the progressive metabolic deterioration that characterize active type 2 diabetes. The compounding value of that decade is substantial.

It is a reason to be honest about what the intervention requires: not a temporary diet but a sustained change in the conditions that drove ectopic fat accumulation in the first place.

The honest summary

Type 2 diabetes develops over a decade, during which the body’s compensatory mechanisms keep blood glucose looking normal while insulin resistance and ectopic fat accumulation advance. The diagnosis arrives when beta cell function can no longer sustain compensation, typically 10 to 15 years after the metabolic process began.

Remission is achievable. The DiRECT trial demonstrated 46 percent remission rates at one year and 86 percent in those losing 15 kg or more. The mechanism is the clearance of liver and pancreatic fat, restoring first-phase insulin secretion. Exercise contributes through AMPK-driven GLUT4 translocation and through the structural expansion of the glucose disposal reservoir that skeletal muscle represents. Dietary composition affects the glycemic environment. Sleep affects insulin sensitivity continuously.

The window closes as beta cell exhaustion progresses. Intervention is most effective earliest. The 374 million people with impaired glucose tolerance are in the window now.

The metabolic markers that make the pre-diabetic decade visible, fasting insulin, HOMA-IR, HbA1c, are covered in detail in the metabolic health article.

---

References

1. Lean MEJ, Leslie WS, Barnes AC, et al. (2018). Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet, 391(10120), 541–551. https://pubmed.ncbi.nlm.nih.gov/29221645/
2. Hallberg SJ, McKenzie AL, Williams PT, et al. (2018). Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year: an open-label, non-randomized, controlled study. Diabetes Therapy, 9(2), 583–612. https://pubmed.ncbi.nlm.nih.gov/29417495/
3. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. (2009). Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet, 373(9682), 2215–2221. https://pubmed.ncbi.nlm.nih.gov/19515410/
4. Taylor R. (2013). Type 2 diabetes: etiology and reversibility. Diabetologia, 56(6), 1047–1058. https://pubmed.ncbi.nlm.nih.gov/23474874/
5. International Diabetes Federation. (2021). IDF Diabetes Atlas, 10th edition. Brussels: IDF. https://www.diabetesatlas.org/
6. Pan XR, Yang WY, Li GW, Liu J; Da Qing Diabetes Prevention Study Group, et al. (2018). 40-year follow-up of the Da Qing Diabetes Prevention Study. Lancet Diabetes and Endocrinology, 6(12), 924–934. https://pubmed.ncbi.nlm.nih.gov/30219316/
7. Spiegel K, Leproult R, Van Cauter E. (1999). Impact of sleep debt on metabolic and endocrine function. Lancet, 354(9188), 1435–1439. https://pubmed.ncbi.nlm.nih.gov/10543671/
8. Estruch R, Ros E, Salas-Salvadó J, et al. (2013). Primary prevention of cardiovascular disease with a Mediterranean diet. New England Journal of Medicine, 368(14), 1279–1290. https://pubmed.ncbi.nlm.nih.gov/23432189/
9. Knowler WC, Barrett-Connor E, Fowler SE, et al. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 346(6), 393–403. https://pubmed.ncbi.nlm.nih.gov/11832527/